AAV production system enables scalable gene therapy workflows

Thermo Fisher Scientific’s New Free Gibco AAV-MAX Helper AAV Production System Helps Reduce Production Costs and Streamline the Transition from Research to Clinical Environments

To address the need to make adeno-associated virus (AAV) production more efficient and scalable, Thermo Fisher Scientific has launched the free Gibco AAV-MAX Helper production system. This complete and optimized solution simplifies the workflow of AAV vectors. The all-in-one AAV-MAX system increases productivity and cost-efficiency by delivering high viral titers using Viral Production Cells 2.0, a novel 293F-derived mammalian cell line documented by cloning.

AAV is crucial for gene therapy; more than 1,300 unique gene therapy products are currently in development, and almost half depend on AAV. The ability to increase production is essential to reduce costs and accelerate research to market.

Amy Butler, President of the Biosciences Division at Thermo Fisher, said: “AAV has an efficacy and safety profile that makes it an ideal therapeutic vector and one of the essential biological delivery methods for recent advances in gene therapy. The new AAV production system is part of our end-to-end workflow solutions to meet the growing demand for cost-effective and scalable viral vector production.Gain access to products and services designed specifically for cell therapy research and genetics, with direct visibility into clinical manufacturing, empowers our biotechnology and biopharmaceutical partners. “

The AAV-MAX system was developed to adapt from shake flasks to bioreactors. The system is designed to streamline the transition from research to commercial manufacturing when combined with the active development of regulatory compliant reagents. On average, the system allows viral vector researchers and developers to save 25% on plasmid DNA usage and 50% on production costs compared to polyethyleneimine (PEI) -based mammalian production systems. . When used in conjunction with Thermo Fisher’s extensive portfolio of gene therapy products, developers can smoothly transition into commercial production to help deliver therapies to patients.

Want the latest science news delivered straight to your inbox? Become a Free SelectScience Member Today >>

Comments are closed.